Cargando…

Ginsenoside Rg3 Attenuates Angiotensin II-Mediated Renal Injury in Rats and Mice by Upregulating Angiotensin-Converting Enzyme 2 in the Renal Tissue

Angiotensin II- (Ang II-) mediated renal injury represents a major pathogenetic mechanism in most chronic kidney diseases. Our previous research demonstrated that ginsenoside Rg3 (Rg3) attenuates Ang II elevation in the myocardium in spontaneously hypertensive rats (SHR). It is possible that Rg3 has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hui, Jiang, Yichuan, Li, Min, Yu, Xiaofeng, Sui, Dayun, Fu, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915024/ https://www.ncbi.nlm.nih.gov/pubmed/31885658 http://dx.doi.org/10.1155/2019/6741057

Ejemplares similares

Ginsenoside Rc Ameliorates Endothelial Insulin Resistance via Upregulation of Angiotensin-Converting Enzyme 2
por: Wang, Yaozhen, et al.
Publicado: (2021)

Ginsenoside Rg3 induces ginsenoside Rb1-comparable cardioprotective effects independent of reducing blood pressure in spontaneously hypertensive rats
por: Jiang, Yichuan, et al.
Publicado: (2017)

Ginsenoside Rg3 has effects comparable to those of ginsenoside re on diabetic kidney disease prevention in db/db mice by regulating inflammation, fibrosis and PPARγ
por: Sui, Zhe, et al.
Publicado: (2023)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

What is the association of acute renal failure, angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in a young patient?
por: Yüksel, Selçuk, et al.
Publicado: (2013)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain
por: Hernández, Ángel Alonso, et al.
Publicado: (2010)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Ginsenoside Re Improves Inflammation and Fibrosis in Hepatic Tissue by Upregulating PPARγ Expression and Inhibiting Oxidative Stress in db/db Mice
por: Jiang, Yichuan, et al.
Publicado: (2021)

Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension
por: Zhang, Jingsi, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes
por: Xiao, Fengxia, et al.
Publicado: (2012)

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Tissue Specificity of Human Angiotensin I-Converting Enzyme
por: Kryukova, Olga V., et al.
Publicado: (2015)

Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population
por: Zheng, Cai-Mei, et al.
Publicado: (2019)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Resistive index as a predictor of renal progression in patients with moderate renal dysfunction regardless of angiotensin converting enzyme inhibitor or angiotensin receptor antagonist medication
por: Kim, Jae Hoon, et al.
Publicado: (2017)

Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis
por: Oudit, Gavin Y., et al.
Publicado: (2006)

Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms
por: Lamblin, Nicolas, et al.
Publicado: (2003)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Renal oxygen content is increased in healthy subjects after angiotensin-converting enzyme inhibition
por: Stein, Anna, et al.
Publicado: (2012)

Angiotensin-Converting Enzyme 2 in the Pathogenesis of Renal Abnormalities Observed in COVID-19 Patients
por: Azinheira Nobrega Cruz, Nayara, et al.
Publicado: (2021)

20(S)-Ginsenoside Rg2 attenuates myocardial ischemia/reperfusion injury by reducing oxidative stress and inflammation: role of SIRT1
por: Fu, Wenwen, et al.
Publicado: (2018)

Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Angiotensin-converting enzyme: II. Pulmonary endothelial cells in culture.
por: Ryan, U S, et al.
Publicado: (1980)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer’s disease brain
por: Ding, Qiyue, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o41in0v3le8a5ddu4hsun5rknq